Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7792833 | 0.71 | ATM (0.40) | ATMKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL51544 | 0.68 | ATM (0.41) | ATM | |
| Hydrochloric Acid SCHEMBL10501335 | 0.67 | ATM (0.40) | ATM | |
| SCHEMBL5259264 | 0.65 | ATM (0.48) | ATMKDM4EMEN1KMT2AGPR3 | |
| SCHEMBL8424490 | 0.65 | ATM (0.48) | ATMKDM4EMEN1KMT2AGPR3 | |
| SCHEMBL3535166 | 0.65 | ATM (0.48) | ATMKDM4EMEN1KMT2AGPR3 | |
| SCHEMBL4620642 | 0.65 | ATM (0.48) | ATMKDM4EMEN1KMT2AGPR3 | |
| SCHEMBL4559941 | 0.65 | ATM (0.48) | ATMKDM4EMEN1KMT2AGPR3 | |
| SCHEMBL6887470 | 0.65 | CYP2A6 (0.43) | KDM4EALDH1A1HSD17B10GPR3CYP1A2 | |
| SCHEMBL5250885 | 0.63 | ATM (0.45) | ATMKDM4EALDH1A1GPR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| EP-2163538-B1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-01-25 | — | — | EP | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| EP-2163538-A1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | Topharman Shanghai Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | NQO1, KAT2A, HDAC2 | ATM 1814/4885KDM4E 529/4885ALDH1A1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.